Maria Kavianpour1, Hossein Khadem Haghighian2,3, Mahnaz Ghadimi4, Farshad Foroughi5, Sima Hashemipour6, Mohammadreza Rashidi Nooshabadi7, Mohammad Hossein Ahmadi8, Mojtaba Ghadimi Yari9. 1. Department of Tissue Engineering and Applied Cell Sciences, Faculty of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran. Kavianpour.maria@gmail.com. 2. Department of Nutrition, School of Health, Qazvin University of Medical Sciences, Qazvin, Iran. khademnut@yahoo.com. 3. Metabolic Diseases Research Center, Research Institute for Prevention of Non-Communicable Diseases, Qazvin University of Medical Sciences, Qazvin, Iran. khademnut@yahoo.com. 4. Department of Nutrition, School of Health, Qazvin University of Medical Sciences, Qazvin, Iran. 5. Department of Immunology, School of Medicine, Qazvin University of Medical Sciences, Qazvin, Iran. 6. Metabolic Diseases Research Center, Research Institute for Prevention of Non-Communicable Diseases, Qazvin University of Medical Sciences, Qazvin, Iran. 7. Department of Pharmacology, School of Pharmacy, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran. 8. Department of Laboratory Sciences, School of Allied Medical Sciences, Qazvin University of Medical Sciences, Qazvin, Iran. 9. Determinants of Chemistry, Amirkabir University of Technology, Tehran, Iran.
Abstract
BACKGROUND: The beneficial effects of polyphenols have been reported. This study aimed to investigate the effect of oral Ellagic acid (EA) supplement on insulin resistance (IR) and Fetuin-A and serum sirtuin1 (SIRT1) in type 2 diabetics. METHODS: In this double-blind, randomized clinical trial, 44 diabetic patients were selected. Patients were assigned to the intervention group (22 subjects) and placebo (22 subjects) and received a capsule containing 180 mg of EA per day or placebo for eight weeks, respectively. At the beginning and end of the study, anthropometric indices, fasting plasma glucose (FPG), plasma insulin level, IR, Fetuin-A, and SIRT1 were measured. Statistical analysis was performed using SPSS software. RESULTS: At the beginning and end of the study, there was no significant difference between the two groups regarding anthropometric indices (P > 0.05). At the end of the survey, EA supplementation significantly reduced FPG, insulin, IR, and Fetuin-A and increased SIRT1 levels compared with the placebo group (P < 0.05). However, these changes were not significant in the placebo group (P > 0.05). CONCLUSION: EA with antioxidant properties plays an essential role in reducing the macrovascular and microvascular complications of diabetes by reducing inflammation and insulin resistance. Trial registration The protocol of this clinical trial is registered with the Iranian Registry of Clinical Trials ( http://www.IRCT.IR , identifier: IRCT20141025019669N13).
RCT Entities:
BACKGROUND: The beneficial effects of polyphenols have been reported. This study aimed to investigate the effect of oral Ellagic acid (EA) supplement on insulin resistance (IR) and Fetuin-A and serum sirtuin1 (SIRT1) in type 2 diabetics. METHODS: In this double-blind, randomized clinical trial, 44 diabeticpatients were selected. Patients were assigned to the intervention group (22 subjects) and placebo (22 subjects) and received a capsule containing 180 mg of EA per day or placebo for eight weeks, respectively. At the beginning and end of the study, anthropometric indices, fasting plasma glucose (FPG), plasma insulin level, IR, Fetuin-A, and SIRT1 were measured. Statistical analysis was performed using SPSS software. RESULTS: At the beginning and end of the study, there was no significant difference between the two groups regarding anthropometric indices (P > 0.05). At the end of the survey, EA supplementation significantly reduced FPG, insulin, IR, and Fetuin-A and increased SIRT1 levels compared with the placebo group (P < 0.05). However, these changes were not significant in the placebo group (P > 0.05). CONCLUSION:EA with antioxidant properties plays an essential role in reducing the macrovascular and microvascular complications of diabetes by reducing inflammation and insulin resistance. Trial registration The protocol of this clinical trial is registered with the Iranian Registry of Clinical Trials ( http://www.IRCT.IR , identifier: IRCT20141025019669N13).
Entities:
Keywords:
Diabetes type 2; Ellagic acid; Glycemic index; Insulin resistance
Authors: Van Dinh Tran; Van Vuong Do; Ngoc Minh Pham; Chung Thanh Nguyen; Nguyen Tuyet Xuong; Jonine Jancey; Andy H Lee Journal: Eval Health Prof Date: 2018-12-19 Impact factor: 2.651
Authors: Jill C Milne; Philip D Lambert; Simon Schenk; David P Carney; Jesse J Smith; David J Gagne; Lei Jin; Olivier Boss; Robert B Perni; Chi B Vu; Jean E Bemis; Roger Xie; Jeremy S Disch; Pui Yee Ng; Joseph J Nunes; Amy V Lynch; Hongying Yang; Heidi Galonek; Kristine Israelian; Wendy Choy; Andre Iffland; Siva Lavu; Oliver Medvedik; David A Sinclair; Jerrold M Olefsky; Michael R Jirousek; Peter J Elliott; Christoph H Westphal Journal: Nature Date: 2007-11-29 Impact factor: 49.962
Authors: Esther Ramírez-Moreno; José Arias-Rico; Reyna Cristina Jiménez-Sánchez; Diego Estrada-Luna; Angélica Saraí Jiménez-Osorio; Quinatzin Yadira Zafra-Rojas; José Alberto Ariza-Ortega; Olga Rocío Flores-Chávez; Lizbeth Morales-Castillejos; Eli Mireya Sandoval-Gallegos Journal: Foods Date: 2022-04-25